IL-STERN-PINBALL-INC
Stern Pinball, Inc. launches a new line of pinball machines celebrating the iconic, genre-defining James Bond films. The James Bond 007 cornerstone series features the original 007 actor, Sean Connery, available in Pro Edition, Premium Edition, and Limited Edition (LE). Stern Pinball will also release a special James Bond 007 60th Anniversary Limited Edition pinball machine featuring all six James Bond actors.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220922005077/en/
James Bond 007 Pinball Pro Edition (Photo: Business Wire)
In Dr. No (1962) Sean Connery propelled 007 into the cultural zeitgeist, bringing the legendary literary figure to life through adrenalized action sequences, ground-breaking gadgets and effects, memorable characters, and timeless villains.
Stern’s James Bond 007 cornerstone pinball machine will highlight film footage and iconic music from the films that built the 007 legend: Dr. No, From Russia With Love (1963), Goldfinger (1964), Thunderball (1965), You Only Live Twice (1967), and Diamonds Are Forever (1971). Players are immersed into the world of espionage in this action-packed pinball experience, tackling assignments, teaming up with key allies, and stopping SPECTRE’s villainous schemes.
Gather gadgets from Q Branch as pinballs get ejected through the roof of a custom sculpted Aston Martin DB5. Break through the Osato Chemicals drop targets to battle SPECTRE at the Bird 1 rocket base. And hold your breath on the gravity defying, magnetic jetpack as it transports pinballs across the playfield.
James Bond 007 pinball machines include Stern’s award-winning Insider Connected™ system, which enables players to interact with the game and a global network of players in a variety of ways. Through Insider Connected, players can track progress, earn new game-specific achievements, engage with the player community, and participate in promotions and Challenge Quests. Insider Connected also provides an operator-focused toolset to drive location play through Location Leaderboards, build player loyalty, analyze performance, make adjustments remotely, and maintain the machines. Registration for Insider Connected is available at insider.sternpinball.com/.
Limited to 1,000 machines globally, the highly collectible cornerstone Limited Edition includes an exclusive full-color mirrored backglass inspired by Thunderball, masterfully adapted cabinet artwork, custom high gloss and powder-coated pinball armor, a custom designer-autographed bottom arch, exclusive inside art blades, upgraded audio system, anti-reflection pinball playfield glass, shaker motor, a sequentially numbered plaque, and a Certificate of Authenticity signed by Stern Chairman Gary Stern and President Seth Davis.
Stern’s James Bond 007 60th Anniversary Limited Edition pinball machines will immerse players in the history of 007. Limited to 500 machines globally, the highly collectible 60th Anniversary Limited Edition offers players a retro-inspired playfield packed with exciting mechanical action. Control the chaos from Oddjob’s kinetic spinning disc hat, survive tactical precision shots against 10 drop targets, escape SPECTRE’s evil henchmen navigating pinballs through 4 fast-flowing optical spinners, learn assignments through an in-playfield LCD screen, and rack up high scores on classic-style score reels.
“James Bond is as timeless as pinball. Partnering with EON Productions/Danjaq, MGM Studios and Aston Martin, we created a pinball adventure capturing the suspense, action, and humor from this beloved film series,” said Gary Stern, Chairman and CEO. “Get connected today and become a legend.”
Fittingly, the new James Bond 007 pinball machines will be on show for the first time to media and public in London. On September 26th the games will be on display and available to play as part of the Bond-themed Christie’s Late, a public event celebrating the forthcoming Christie’s Sixty Years of James Bond Charity Auction. Shortly after, they will be a part of the James Bond at 60 weekend at the British Film Institute on the South Bank, September 30th-October 2nd.
Pricing and Availability:
Manufacturer’s Suggested Retail Price (“MSRP”)*:
*MSRP for sales to USA end-users, before any VAT, GST, Sales Tax, Duties, or other taxes.
Pro Edition: $US 6,999
Premium Edition: $US 9,699
Limited Edition: $US 12,999
60th Anniversary Limited Edition: CALL FOR PRICE
James Bond 007 pinball machines and accessories are available now through authorized Stern Pinball distributors and dealers around the world. Pro and Premium Editions will also be available at 007Store.com.
About Stern Pinball, Inc.
Stern Pinball, Inc. is a global lifestyle brand based on the iconic and outrageously fun modern American game of pinball. Headquartered minutes from Chicago’s O’Hare International Airport in the heart of North America, the company creates, designs, engineers, manufactures, markets, and distributes a full line of technologically advanced terrestrial and digital pinball games, parts, accessories, and merchandise. Stern Pinball serves digital, consumer, commercial, and corporate markets around the globe.
Recent Stern Pinball titles include Rush, Godzilla, The Mandalorian, Led Zeppelin, Avengers: Infinity Quest, Teenage Mutant Ninja Turtles, Stranger Things, Elvira’s House of Horrors, Jurassic Park, Black Knight: Sword of Rage, The Munsters, The Beatles, Deadpool, Iron Maiden, Guardians of the Galaxy, Star Wars, Aerosmith, Ghostbusters, KISS, Metallica, Game of Thrones, The Walking Dead, Star Trek, AC/DC, Batman, and Spider-Man. A broad range of players enjoy Stern Pinball’s games from professional pinball players who compete in high-stakes competitions around the globe to novice players who are discovering the allure of the silver ball for the first time. To join the fun and learn more, please visit www.sternpinball.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220922005077/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse
Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
